Nanoform Finland Oyj

Nanoform Finland Oyj maintains a strong liquidity position with EUR 24.0 million in cash and equivalents, representing 56% of its total assets. The company's debt-to-equity ratio of 0.15 indicates a conservative capital structure, with long-term debt of EUR 6.2 million compared to total equity of EUR 42.8 million. The enterprise value to revenue ratio of 9.82 suggests a premium valuation relative to its EUR 3.5 million revenue base. The company's profitability metrics are negative, with a return on equity of -41.84% and a net loss of EUR 17.9 million. These results contrast with the industry's median return on equity of 12.5% and median net profit margin of 18.2% for the Biotechnology & Medical Research sector. The operating cash flow of -EUR 17.7 million and free cash flow of -EUR 15.8 million highlight the company's current cash burn rate, which is significantly higher than the sector median of -EUR 5.2 million for early-stage biotech firms. Nanoform Finland Oyj operates through a single disclosed segment, with all production, research, and development functions based in Finland. The company has one subsidiary, Nanoform USA Inc., but no geographic revenue breakdown is available in the latest financials. The lack of geographic diversification and reliance on a single subsidiary may expose the company to regional economic and regulatory risks. The company's revenue growth trajectory is uncertain, with no historical growth data provided in the latest financials. Analysts have set a mean price target of EUR 2.12, implying a 244% upside from the current market price of EUR 0.614. However, the company's negative operating cash flow and high cash burn rate suggest that it may require additional capital to sustain operations beyond the current EUR 24.0 million cash reserves. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's dilution potential is also low, as shares outstanding remain unchanged between basic and diluted counts at 85.7 million. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to share dilution. Recent events include the publication of the latest financial snapshot and analyst price targets. No material filings or transcripts were disclosed in the provided data. The company's strategy to sell nanotechnological services widely to minimize dependence on single customers or projects is consistent with its current business model.